In vivoimaging of bioluminescentPseudomonas aeruginosain an acute murine airway infection model

Munder, Antje; Wölbeling, Florian; Klockgether, Jens; Wiehlmann, Lutz; Tümmler, Burkhard

doi:10.1111/2049-632x.12184

Cited by 15 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other methods for non-invasive disease monitoring include the use of genetically engineered bioluminescent bacteria (94,95). The Photorhabdus luminescence lux operon is one of the best-studied operons to be utilized as a marker (96)(97)(98).…”

Section: Disease Endpoints For Translational Studiesmentioning

confidence: 99%

Animal models of hospital-acquired pneumonia: current practices and future perspectives

Bielen¹,

Jongers²,

Malhotra-Kumar³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Lower respiratory tract infections are amongst the leading causes of mortality and morbidity worldwide. Especially in hospital settings and more particularly in critically ill ventilated patients, nosocomial pneumonia is one of the most serious infectious complications frequently caused by opportunistic pathogens.Pseudomonas aeruginosa is one of the most important causes of ventilator-associated pneumonia as well as the major cause of chronic pneumonia in cystic fibrosis patients. Animal models of pneumonia allow us to investigate distinct types of pneumonia at various disease stages, studies that are not possible in patients.Different animal models of pneumonia such as one-hit acute pneumonia models, ventilator-associated pneumonia models and biofilm pneumonia models associated with cystic fibrosis have been extensively studied and have considerably aided our understanding of disease pathogenesis and testing and developing new treatment strategies. The present review aims to guide investigators in choosing appropriate animal pneumonia models by describing and comparing the relevant characteristics of each model using P. aeruginosa as a model etiology for hospital-acquired pneumonia. Key to establishing and studying these animal models of infection are well-defined end-points that allow precise monitoring and characterization of disease development that could ultimately aid in translating these findings to patient populations in order to guide therapy. In this respect, and discussed here, is the development of humanized animal models of bacterial pneumonia that could offer unique advantages to study bacterial virulence factor expression and host cytokine production for translational purposes.

show abstract

Section: Disease Endpoints For Translational Studiesmentioning

confidence: 99%

Animal models of hospital-acquired pneumonia: current practices and future perspectives

Bielen¹,

Jongers²,

Malhotra-Kumar³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…After infection, mortality and body weight were monitored once a day over one week. In vivo bioluminescence imaging was performed using a luciferase-expressing Pseudomonas aeruginosa strain as published previously [23] and infecting mice with and 5×10 7 CFU intratracheally. Bioluminescence imaging was performed 24h post infection using an IVIS spectrum preclinical in vivo imaging read-out system (Perkin Elmer).…”

Section: Methodsmentioning

confidence: 99%

“…A GFP-expressing Pseudomonas aeruginosa strain was used for microscopical imaging studies. A luciferase-expressing Pseudomonas aeruginosa strain was used for bioimaging studies as published previously [23]. …”

Section: Methodsmentioning

confidence: 99%

“…Non-invasive in vivo OI measurements were conducted 24h after intratracheal infection of Cxcr1 −/− and Cxcr1 +/+ mice with luciferase-expressing Pseudomonas aeruginosa bacteria (TBCF10839 isogenic mutant D8A6, 5×10 7 CFU/mouse) as published previously [23]. During measurements, mice were anesthetized by inhalation of isoflurane-O2 (1.5% Forane, Abbott GmbH, Wiesbaden, Germany) and body temperature was maintained at 37°C.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

CXCR1 Regulates Pulmonary Anti-Pseudomonas Host Defense

et al. 2016

View full text Add to dashboard Cite

Pseudomonas aeruginosa is a key opportunistic pathogen causing disease in cystic fibrosis (CF) and other lung diseases such as chronic obstructive pulmonary disease (COPD). However, the pulmonary host defense mechanisms regulating anti-P. aeruginosa immunity remain incompletely understood. Here we demonstrate, by studying an airway P. aeruginosa infection model, in vivo bioluminescence imaging, neutrophil effector responses and human airway samples, that the chemokine receptor CXCR1 regulates pulmonary host defense against P. aeruginosa. Mechanistically, CXCR1 regulates anti-Pseudomonas neutrophil responses through modulation of reactive oxygen species and interference with Toll-like receptor 5 expression. These studies define CXCR1 as a novel, noncanonical chemokine receptor that regulates pulmonary anti-Pseudomonas host defense with broad implications for CF, COPD and other infectious lung diseases.

show abstract

“…Recent developments in these models entail the inoculation of the animals with endogenously luminescent bacteria so that the animals can be followed in real time after APDT [210]. The intensity of luminescence can be directly correlated to the extent of the infection [210,218]. Genetically modified E. coli and P. aeruginosa via transformation of a plasmid containing the P. luminescens lux operon could stably generate bioluminescence [210].…”

Section: In Vivo and Clinical Status Quo Of Antibacterial Photodynamimentioning

confidence: 99%

Antibacterial photodynamic therapy: overview of a promising approach to fight antibiotic-resistant bacterial infections

et al. 2015

View full text Add to dashboard Cite

Antibacterial photodynamic therapy (APDT) has drawn increasing attention from the scientific society for its potential to effectively kill multidrug-resistant pathogenic bacteria and for its low tendency to induce drug resistance that bacteria can rapidly develop against traditional antibiotic therapy. The review summarizes the mechanism of action of APDT, the photosensitizers, the barriers to PS localization, the targets, the in vitro-, in vivo-, and clinical evidence, the current developments in terms of treating Gram-positive and Gram-negative bacteria, the limitations, as well as future perspectives. Relevance for patients: A structured overview of all important aspects of APDT is provided in the context of resistant bacterial species. The information presented is relevant and accessible for scientists as well as clinicians, whose joint effort is required to ensure that this technology benefits patients in the post-antibiotic era.

show abstract

In vivoimaging of bioluminescentPseudomonas aeruginosain an acute murine airway infection model

Cited by 15 publications

References 21 publications

Animal models of hospital-acquired pneumonia: current practices and future perspectives

Animal models of hospital-acquired pneumonia: current practices and future perspectives

CXCR1 Regulates Pulmonary Anti-<b><i>Pseudomonas</i></b> Host Defense

Antibacterial photodynamic therapy: overview of a promising approach to fight antibiotic-resistant bacterial infections

Contact Info

Product

Resources

About